Genomics

Dataset Information

0

Examination of microRNA expression in pre- and post-treatment plasma samples of 3 patients


ABSTRACT: Drug resistance often tempers the clinical benefit of chemotherapy in human malignant tumors. The potential chemosensitization of low-dose decitabine has been evident both preclinically and in previous phase I trials. Emerging data showed that miRNAs play an important role as a prognostic factor for cancer survival. Given that the biopsy tumor tissue was often not available, especially for patients with relapsed or refractory cancer, plasma RNA provided a valuable source for biomarker development. In order to establish predictive biomarker signature for the clinical efficacy of the decitabine-primed chemotherapy, we evaluated the expression of plasma miRNAs via high throughput microRNA sequencing. We performed miRNA-seq on a training set of 2 partial response (PR) patients and 1 progressive disease (PD) patients, and revealed preliminary data that plasma miRNA expression signature may serve as putative predictive markers of the low-dose decitabine primed chemotherapy. The clinical responses were assessed in a blinded manner according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

ORGANISM(S): Homo sapiens

PROVIDER: GSE91089 | GEO | 2016/12/15

SECONDARY ACCESSION(S): PRJNA356856

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-04-13 | GSE146722 | GEO
2016-06-30 | E-GEOD-72686 | biostudies-arrayexpress
2024-02-23 | PXD047873 | Pride
2021-06-01 | GSE154540 | GEO
2024-08-27 | GSE270967 | GEO
2020-07-21 | GSE154703 | GEO
2015-08-18 | GSE69795 | GEO
2022-01-03 | GSE192834 | GEO
2022-01-03 | GSE192744 | GEO
2022-01-03 | GSE192833 | GEO